De novo EGFR T790M mutation modifies outcome to second-line erlotinib in non-small cell lung cancer (NSCLC) according to metastatic site and upfront chemotherapy

被引：0
|
作者：
Rosell, Rafael [1 ]
Angel Molina, Miguel [2 ]
Javier Sanchez, Jose [3 ]
Taron, Miguel [1 ]
Benlloch, Susana [2 ]
Moran, Teresa [1 ]
Carcereny, Enric [1 ]
Cardenal, Felipe [4 ]
Massuti, Bartomeu [5 ]
Magri, Ignacio [2 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain
[2] Dexeus Univ Inst, Pangaea Biotech, Barcelona, Spain
[3] Autonomous Univ Madrid, E-28049 Madrid, Spain
[4] Hosp Duran & Reynals, Catalan Inst Oncol, Barcelona, Spain
[5] Hosp Gen Alicante, Alicante, Spain
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-4112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4112
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Non-Small Cell Lung Cancer with De Novo EGFR T790M Mutation: Clinical Features of 22 Cases
    Heo, Mi Hwa
    Kim, Hee Kyung
    Lee, Hansang
    Cho, Jinhyun
    Park, Juyoun
    Jeong, Su-Mi
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1237 - S1238
  • [2] EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
    Sonoda, Tomoaki
    Nishikawa, Shingo
    Sakakibara, Rie
    Saiki, Masafumi
    Ariyasu, Ryo
    Koyama, Junji
    Kitazono, Satoru
    Yanagitani, Noriko
    Horiike, Atsushi
    Ohyanagi, Fumiyoshi
    Ninomiya, Hironori
    Ishikawa, Yuichi
    Nishio, Makoto
    [J]. RESPIRATORY MEDICINE CASE REPORTS, 2018, 24 : 19 - 21
  • [3] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [4] Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation
    Dogan, I.
    Gurbuz, M.
    Paksoy, N.
    Khanmamadov, N.
    Vatansever, S.
    Saip, P.
    Demirkazik, A.
    Aydiner, A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1351 - S1351
  • [5] Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site
    Uematsu, Shinya
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [6] Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
    Kuang, Yanan
    Rogers, Andrew
    Yeap, Beow Y.
    Wang, Lilin
    Makrigiorgos, Mike
    Vetrand, Kristi
    Thiede, Sara
    Distel, Robert J.
    Jaenne, Pasi A.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (08) : 2630 - 2636
  • [7] Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies
    Rosell, R.
    Molina, M. A.
    Costa, C.
    Taron, M.
    Bertran-Alamillo, J.
    Mayo, C.
    Benlloch, S.
    Moran, T.
    Cardenal, F.
    Porta, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [9] Detection of EGFR T790M Mutation in Pericardial Effusion from a Non-Small Cell Lung Cancer Patient with Erlotinib Therapy
    Sakai, Asao
    Kasahara, Kazuo
    Sone, Takashi
    [J]. CASE REPORTS IN ONCOLOGY, 2013, 6 (01): : 15 - 20
  • [10] Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
    Liao, Bin-Chi
    Griesing, Sebastian
    Yang, James Chih-Hsin
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
12345